Multiple Myeloma Prognosis (ISS)
The new International Staging System has been validated in patients from North America, Europe, Asia; in patient less than or greater than age 65; and in patients receiving conservative therapy or high-dose therapy en route to autologous transplantation. Based exclusively on the beta 2 microglobulin and albumin levels at diagnosis, the ISS relies on simple and available lab parameters, and thus may be more objective than previous staging systems, including the Salmon-Durie system based on clinical variables. B2M is thought to reflect underlying tumor burden, renal, and potentially immune function, while the prognostic significance of albumin is not completely understood, although it is hypothesized that IL-6 produced in the myeloma microenvironment may impair hepatic albumin production.
Greipp PR et al.
Journal of Clinical Oncology 2005 May 20, 23 (15): 3412-20
Durie BGM, Salmon SE.
Cancer 1975, 36 (3): 842-54
The Multiple Myeloma Prognosis (ISS) calculator is created by QxMD.